Longeveron (LGVN) Other Working Capital Changes (2020 - 2026)
Longeveron (LGVN) recorded quarterly Other Working Capital Changes of $62000.0 in Q1 2026, up 128.7% quarter-over-quarter from -$216000.0 in Q4 2025, and down 3.12% on a YoY basis from $64000.0 in Q1 2025.
Longeveron (LGVN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Longeveron's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $62000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 3.12% year-over-year to $62000.0; the TTM figure through Mar 2026 stood at -$27000.0 (up 59.7% YoY), while the FY2025 annual figure was -$25000.0, up 63.24% from the prior year.
- Other Working Capital Changes was $62000.0 for Q1 2026 at Longeveron, up from -$216000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $702000.0 in Q2 2022 to a low of -$698000.0 in Q3 2022.
- Historically, Other Working Capital Changes has averaged -$3941.2 across 5 years, with a median of $2000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes slumped 1339.13% in 2023, then soared 3050.0% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at -$46000.0 in 2022, then plunged by 1339.13% to -$662000.0 in 2023, then surged by 60.88% to -$259000.0 in 2024, then increased by 16.6% to -$216000.0 in 2025, then soared by 128.7% to $62000.0 in 2026.
- The last three Other Working Capital Changes figures came in at $62000.0 (Q1 2026), -$216000.0 (Q4 2025), and -$405000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | -216,000.00 |
| Dec 31, 2025 | -216,000.00 |
| Sep 30, 2025 | -405,000.00 |
| Sep 30, 2025 | -405,000.00 |
| Jun 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 532,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Sep 30, 2024 | 180,000.00 |
| Sep 30, 2024 | 180,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | -662,000.00 |
| Dec 31, 2023 | -662,000.00 |